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Abstract: Background: Many pediatric transplant (TX) centers routinely monitor Epstein-Barr (EB) viral load (VL) by 
real time quantitative PCR and intervene to prevent post-transplant lymphoproliferative disorder (PTLD). Some children 
develop asymptomatic persistent VL (PVL). Outcome of different interventions in preventing PTLD and other undesired 
effects on acute rejection (AR), graft failure (GF) and function amongst children with asymptomatic PVL is not known. 
Methods: NAPRTCS centers invited to enter data on children with asymptomatic PVL (≥ 6 months) into the EB VL 
registry. Comparison group included children into the NAPRTCS TX arm during the same period without PVL or VL 
monitoring. EB VL were arbitrarily divided into low (1-10), medium (>10-100) and high (>100times detection limit for 
the center) ratio. 
Results: Of 645 children (18 centers), 85 (13.2%) developed onset of PVL at a mean of 6.4 ± 6.3 months post-TX. PVL 
children were more likely to be younger (< 5 years) at TX and less likely to be African-American and majority (75.3%) 
was mismatched for EBV (donor EBV IgG positive and recipient negative). Thymoglobulin induction was used in 29.4% 
children with PVL versus 37% in controls (p=ns). PTLD developed in 7/85 (8.2%) children with PVL versus 5/560 
(0.9%) controls (p < 0.0001). EB VL ratios were not different in those with and without PTLD. EB PVL as time varying 
covariate did not affect patient survival, GF and AR (HR, 0.85, 0.53 and 0.99). The change in GFR overtime in children 
with PVL was comparable to controls. 
Conclusion: Children with PVL (actual load not predictive) are at increased risk for PTLD, but not for AR, death, GF or 
loss of graft function. 
Keywords: Children, Epstein-Barr virus, kidney transplantation. 
BACKGROUND 
 Post-transplant lymphoproliferative disorder (PTLD) is a 
serious complication in Epstein Barr virus (EBV) naïve 
children [1]. Most cases of PTLD are EBV driven and have 
evidence of EBV infection at diagnosis [2]. With the 
widespread availability of Epstein Barr (EB) viral load (VL) 
assays by real time quantitative polymerase chain reaction 
(RT-qPCR) for clinical purposes, many pediatric centers 
have adopted routine surveillance of their post-transplant 
patients for early detection of EB VL by RT-qPCR [3]. This 
strategy has led to detection of children with asymptomatic 
EB VL including a subset with persistent VL (PVL). Often, 
transplant nephrologists make immunosuppression (IS)  
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adjustments and add other therapies (antiviral medications, 
intravenous immunoglobulin, cytogam, and rituximab) to 
decrease EB VL in order to prevent PTLD. However, 
excessive reduction of IS may lead to acute rejection 
(AR)and graft dysfunction. Outcome of pediatric patients 
with asymptomatic EB PVL and these interventions is not 
well characterized. In pediatric heart transplant (TX) 
recipients, 45% children with PVL developed PTLD [4]. In 
contrast, the rate of progression to PTLD was less than 10% 
in pediatric liver transplant recipients [5]. In this study, we 
sought to ascertain the incidence of PVL and progression 
rate to PTLD in pediatric kidney transplant recipients, as 
well as the impact of different interventions on patient and 
graft survival and graft function. This data was collected 
from 18 pediatric transplant centers participating in the 
North American Pediatric Renal Trials and Collaborative 
Studies Report (NAPRTCS) registry. 
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METHODS 
 NAPRTCS is a voluntary consortium of pediatric 
nephrology centers in the United States and Canada with the 
aim of standardized data collection on patients with chronic 
kidney disease, those receiving dialysis and after transplant 
to help provide pediatric specific benchmarking data to 
improve quality of care for these children. The data elements 
collected and methodology are described in the NAPRTCS 
annual report [6]. The data is entered on line in a password 
protected database. All participating centers (144) have 
approval of their respective institutional review boards to 
enter data into this registry. 
EB PVL Registry 
 EB PVL registry was newly created for this study within 
the NAPRTCS, as data on EB VL was not originally 
collected in the NAPRTCS transplant arm. Each 
participating center routinely measuring post-transplant EB 
VL by RT-q PCR was asked to enter additional information 
on their patients with EB PVL into this registry and given a 
small reimbursement for each completed form. Patients 
meeting the following inclusion criteria were eligible for 
participation in the EB PVL registry: 1. Transplant after 
January 1, 2005, 2. those with persistent (≥2 positive VL or 
≥2/3 of measured VL positive over 6 months) EB VL, 3. 
asymptomatic (no symptoms of EBV infection or PTLD 
prior to first VL detection and over 6 months afterwards 
during viral surveillance), 4. follow-up of at least 1 year after 
fulfilling criteria for EB PVL. After data entry was 
completed, the first author sought clarifications from the 
participating centers through telephone interviews and email 
communications. Other patients enrolled into NAPRTCS 
transplant arm without PVL or VL monitoring from these 18 
centers during the same time served as controls. Of note, 
some of these control patients may have had transient VL or 
progressed to PTLD within 6 months of EB VL detection. 
Data Collected 
 Data on demographics, EBV and cytomegalovirus 
(CMV) serologies of the donor and recipient at transplant, 
induction therapies (monoclonal, polyclonal antibody 
thymoglobulin and no induction), maintenance 
immunosuppression, type of specimen for EB VL assay 
(whole blood, plasma, serum or lymphocytes), and VL 
detection limit of each laboratory was collected. The 
frequency of monitoring of EBV VL was 1-3 months and in 
case of more frequent monitoring in case of positive VL, 
centers were asked to enter only one (highest) value per 
month. In addition, type of intervention after detection of 
first EB VL (reduction in immunosuppression, antiviral 
medications, intravenous immunoglobulin and rituximab), 
information on PTLD, patient and graft survival, acute 
rejection and graft function was collected. Estimated 
Glomerular filtration rate (eGFR) was calculated by using 
modified old Schwartz formula described in the NAPRTCS 
annual report. As there were different assays used for 
measuring EB VL in different centers, EB VL ratio using the 
peak viral load value over 6 months period (measured VL in 
the specimen/VL detection limit for the laboratory) was  
 
calculated and arbitrarily divided into low (1-10), medium 
(>10-100) and high (>100). The incidence of PTLD was 
compared amongst children with different VL ratios to 
assess if incidence of PTLD increased with increasing VL. 
Statistics 
 Demographics and categorical variables between EB 
PVL and controls were compared by chi-square analysis. 
Cox regression model with development of EB PVL used as 
time varying covariate adjusted for age, race and gender was 
used to compare patient survival, graft survival, time to acute 
rejection and to PTLD between those with EB PVL and 
controls. A repeated measures linear regression analysis also 
adjusted for age at transplant, race and gender was used to 
compare eGFR during follow-up between EB PVL and 
controls. P value of <0.05 was considered significant. All 
analyses were conducted using SAS version 9.2 (Cary, NC). 
RESULTS 
Incidence of Asymptomatic EB PVL 
 Eighteen pediatric transplant institutions participating in 
this study enrolled 645 children in the NAPRTCS transplant 
arm from January 2005-April 2011. Of these, 85 were 
reported to have EB PVL (Cumulative incidence 13.2%, 
incidence at each center ranged range between 2.7-32%). 
Onset of EB PVL was first detected at a mean ±SD of 6.4± 
6.3 (median 4.2, range 0-35.5) months after transplant. 
Viral Load Assays 
 Of 18 centers, 13 centers (68 children) had EB VL 
measurement in the whole blood (detection limits of 60-2000 
copies/ml), 4 centers (10 children) in the plasma (detection 
limits of 120-250 copies/ml), 2 centers (5 children) in the 
serum (detection limits of 100-2000 copies/ml), 1 center (2 
children) in the lymphocytes (detection limit 150 copies/105 
lymphocytes). Note that 2 centers had more than one type of 
measurement. 
Risk Factors for EB PVL 
 Young (<5 years of age) and Caucasian children were 
more likely to develop PVL. Thymoglobulin induction was 
not identified as a risk factor for PVL (Table 1). As data on 
the CMV and EBV serostatus was not available in the 
control group since these data are not routinely collected in 
the master transplant registry, CMV and EBV mismatched 
status could not be compared between children with PVL 
and controls. However, of children with EB PVL, 55/73 
(75.3%) were mismatched (Donor + and recipient –) for 
EBV IgG and 37/80 (46.3%) were mismatched for CMV 
IgG. The data were missing for the remaining children. 
Peak Viral Load Ratio Over 6 Months and Induction 
Therapy in EBV Mismatched Children 
 Comparison of peak median VL ratio over 6 months in 
children receiving induction therapy with Thymoglobulin to 
those with anti-IL-2R antibodies in EBV mismatched  
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Age <5 years 34 (40.0) 83 (14.8) <0.0001 






















children is shown in Table 2. Seven children receiving 
induction with other agents or no induction were excluded 
from this analysis. Though median VL ratio was higher in 
children who received induction therapy with Thymoglo-
bulin compared to those with anti-IL-2R antibodies (1500 
versus 92, p 0.044), the proportion of those with low, 
medium and high VL ratio was not different in the two 
groups (p=0.179). 
Table 2. Peak EB VL over 6 months and induction therapy in 
EBV mismatched children. 
 
Peak VL Ratio 





N 21 27 
Low  
1-10 
2 (9.5) 2 (7.4) 
Medium 
>10-100 
4 (19.1) 12 (44.4) 
High 
>100 
15 (71.4) 13 (48.2) 
Median VL 1500 92 
Chi-square p-value = 0.179. 
Median test p-value = 0.044. 
Intervention in EB PVL Patients 
 Of 85 children in the category of EB PVL, 45 (52.9%) 
had reduction or discontinuation of IS. Of 45 children, 19 
(42.2%) had 20-66% reduction in the dose of Mycophenolate 
mofetil (MMF) or Azathioprine (AZA), whereas 26 (57.8%) 
children discontinued MMF or AZA. The CNI dose was 
reduced by 9-71% in 52 (62.2%) children and discontinued 
in 1 child. In 20 (23.5%) children anti-viral medications 
were used; Valganciclovir was used for 1 month->3 years in 
17 children and Cytogam was used in 3 children. In 3 
children, 2-4 doses of Rituximab were used. 
PTLD 
 Of 645 children in the study, 12 developed PTLD with 
the overall incidence of 1.9%. Seven of 85 (8.2%) with PVL 
versus 5/560 (0.9%) control children developed PTLD 
(p=0.0001). PTLD developed at a mean of 16.4 ± 8.9 (med-
ian 15, range 8-33) months after TX in the EB PVL group 
and at a mean of 7.5 ± 1.7 (median 8.4, range 5.4-8.8) months 
after TX in the control group. Amongst 85 children with 
PVL, 0/5 (0.0%) with low, 3/30 (10.0%) with medium and 
4/50 (8%) with high VL ratio developed PTLD (Table 3). 
Amongst children with PVL, 4/7 (57.1%) with PTLD and 41 
/78 (52.6%) children without PTLD had reduction in IS 
(p=ns). Antiviral therapy was used in 1/7 (14.2%) children 
with PTLD versus in 15/78 (19.2%) without PTLD (p=ns). 
Table 3. Peak EBV VL ratio in patients with and without 
PTLD in EBV PVL group. 
 






N 78 7 
Low 
1-10 
5 (6.4) 0 (0.0) 
Medium 
>10-100 
27 (34.6) 3 (42.9) 
High 
>100 
46 (59.0) 4 (57.1) 
Median VL 161 138 
*In patients not developing PTLD, the peak VL over the course of follow-up was used. 
Chi-square p-value = 0.750. 
Median test p-value = 0.719. 
 
PTLD in PVL Group 
 Of 7 children with PTLD, 5 developed PTLD within 1 
year of fulfilling diagnostic criteria for PVL. Of these, 2 had 
received induction with thymoglobulin and 5 received with 
anti-IL-2R antibodies. Of these, 3 children had PTLD limited 
to tonsils and adenoids and were treated with further 
reduction in IS, 4 doses of rituximab and removal of tonsils 
and adenoids. Three children had PTLD limited to lymph 
nodes, 2 were treated with further reduction in IS, and 4 
doses of Rituximab and one with decrease in IS alone. One 
child developed PTLD involving central nervous system and 
was treated with further reduction in IS, rituximab (16 
doses), followed by chemotherapy. All children with PTLD 
were alive with functioning graft at last follow up. 
Effect of EB PVL on the Patient and Graft Survival, 
Acute Rejection and Graft Function 
 EB PVL as time varying covariate adjusted for age, race 
and gender showed no impact on patient and graft survival or 
acute rejection (Table 4). However, it was strongly 
associated with risk of subsequent development of PTLD 
(Table 4 and Fig. 1). The slope of change in eGFR over time 
was not different in children with EB PVL and controls (Fig. 
2). 
DISCUSSION 
 Our data shows that routine monitoring of EB VL by RT-
qPCR identifies a group of children with asymptomatic PVL 
that is at risk for subsequent development of PTLD despite 
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varying degree of empiric interventions. The incidence of 
PTLD amongst these children with PVL was 8.2%, much 
higher than the overall incidence of 1.9% in this study and 
overall reported incidence of PTLD (mostly 1%) amongst 
children after renal transplantation [7]. In this study young, 
Caucasian and EBV mismatched children were more likely 
and African-American children were less likely to develop 
PVL. These demographic and clinical characteristics have 
been identified as risk factors for PTLD in the previous 
studies; however, these characteristics have not been 
previously assessed for development of EB PVL [1, 8-10]. 
Table 4. Effect of EB PVL(Time Varying Covariate adjusted 
for Age, Race and Gender) on patient and graft 
survival, acute rejection and PTLD. 
 
Cox Regression HR 95% CI p-Value 
Patient Survival 0.85  0.10- 7.61  0.88  
Graft Failure 0.53 0.20- 1.38  0.19 
Acute Rejection 0.99 0.56-1.75 0.98 
PTLD 11.05 3.30-37.05 <0.0001 
 
 
Fig. (1). Percent without PTLD in controls and those with EB PVL. 
Kaplan Meier graph showing percentage of children without PTLD 
overtime amongst children with EB PVL and controls. More 
children in PVL group developed PTLD overtime. All children with 
PTLD in the control group developed it in the first 9 months of 
transplantation. 
 Concern has been raised that thymoglobulin may play a 
role in the development of PTLD as it has been shown to 
deplete poly functional T cells in HIV infected kidney 
transplant recipients and activate EBV replication [11]. Even 
though the median VL was high in EBV mismatched 
children receiving induction with thymoglobulin, it was not 
identified as a risk factor for a higher proportion of children 
developing EB PVL in this study. Previous studies have 
provided mixed results regarding the role of polyclonal 
antibodies in increasing risk for PTLD [12], perhaps due to 
intermixing of ALG and equine ATG (Atgam) with rabbit-
ATG (Thymogloubulin). When Thymoglobulin has been 
assessed separately from the other polyclonal antibodies, the 
risk for PTLD has not been elevated [13]. The role of 
Thymoglobulin in EB PVL has not been previously assessed. 
Though the NAPRTCS lumps all polyclonal antibodies into 
one group, our data pertains to Thymoglobulin as during the 
time period of this study, the only polyclonal antibody being 
used for induction is Thymoglobulin and the older agents 
ALG and Atgam are no longer being used for renal 
transplant recipients. 
 
Fig. (2). Change in eGFR overtime in controls and those with EB 
PVL. Shows change in GFR overtime in children with EB PVL and 
controls. The slope of change in eGFR was not different. 
 In our control group, 5 children developed PTLD within 
the first 9 months post-TX (Fig. 1). Of these, 4 were not 
prospectively monitored and EB VL was not detected in one. 
However, all children had evidence of EBV infection on 
histologic examination. It is plausible that prospective 
monitoring in these children may have detected EB VL, as 
negative predictive value of EB VL for EBV infection is 
high [14]. However, it is unlikely that these children would 
have qualified for PVL since the time period between TX 
and PTLD was rather short (7.5 ± 1.7 months). 
 RT-qPCR to measure EB VL varies across different 
centers with 4 different type of specimens (whole blood, 
plasma, serum and lymphocytes) used with different 
laboratory cut-off values. We tried to tackle this problem by 
calculating VL ratio as intra-laboratory variation is small 
[15]. RT-qPCR is the most sensitive method available for 
viral quantitation [16, 17]. The type of specimen needed for 
best clinical correlation with EB VL has not been settled. 
Since EBV causes proliferation of B-cells in the latent stage, 
cell based assays (whole blood and lymphocytes) provide 
estimation of B-cell proliferation induced by latent EBV, 
whereas plasma and serum assays reflect either EBV actively 
released from the B-cells in the replicating phase or passive 
release of latent EBV from breakdown of EBV infected B-
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cells. Though EB VL measurement in the whole blood was 
the most commonly used assay in this study (68 of 85 
children), the actual peak VL was not helpful in predicting 
PTLD. A recent study by Hocker et al. did not find 
correlation between EB VL and duration of VL with PTLD 
or EBV associated diseases [18]. Thus, this study and that by 
Hocker et al. show that EB PVL alone has a low predictive 
value for PTLD. However, prospective EBV VL monitoring 
improves predictability of PTLD over no monitoring at all. It 
was also reassuring that none of the 5 children with low VL 
developed PTLD. Additional assays including measurement 
of EBV specific cytotoxic T-cells generation [19] or B-cell 
dysfunction [20] in addition to measurement of EB VL has 
been suggested to help refine prediction of PTLD. However, 
these assays need further validation for clinical purposes. 
 Reduction of IS has been the cornerstone of preventing 
PTLD [21]. However, there are no guidelines on how to 
reduce IS safely in children with EB PVL to prevent PTLD, 
while not increasing the risk for AR, graft loss or graft 
dysfunction. In this study, we could not show the difference 
in the incidence of PTLD amongst children with PVL who 
had decrease in IS versus those who did not. This may be 
related to the small number of PTLD cases. However, it was 
reassuring that decrease in IS did not lead to increased 
incidence of AR, graft loss and graft dysfunction suggestive 
of the fact that these children were likely to be over 
immunosuppressed. However, we did not assess the risk of 
developing de novo donor specific antibodies (DSA) after 
reduction in IS which may compromise graft function in the 
future. Antiviral medications have been suggested to 
decrease PTLD, but effect of antivirals could not be assessed 
due to small number of children receiving antivirals and low 
incidence of PTLD in this study [22]. 
 Limitations of this study include retrospective registry 
data analysis, lack of uniform control arm (including both 
monitored and not monitored children and possibility of 
including some children with transient VL), and lack of 
standardization of EBV assays though we tried to address the 
later by calculating VL ratio. 
 In conclusion, EB PVL develops in a subset of children 
(most mismatched for EBV) after renal transplantation. 
Young, Caucasian and EBV mismatched children are at risk 
for PVL, whereas thymoglobulin induction does not confer 
increased risk. Children with moderate to high PVL (actual 
load not predictive) are at risk for PTLD despite empiric 
interventions but not at increased risk for AR, death, GF or 
loss of graft function. There is a need for standardization of 
EB VL assays and interventions including immunologic 
monitoring for DSA development to fully elucidate the role 
of EB PVL in pediatric renal transplant recipients. 
Additional assays of EBV specific T-cell cytotoxicity and or 
B-cell function are needed to help further define the risk of 
PTLD amongst children with EB PVL. 
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